Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: whynag who wrote (14320)	3/5/2006 7:35:14 PM
From: stock_hound	Read Replies (1) \| Respond to of 14328

This stock began a bullish runup last week. Is currently at $9.20 (was $8.40). Brendan Farrel, Trinity Biotech President presented an over at the Roth Capital Patners Growth Stock Conference on 2/20/06. His presentation provided a detailed overview of the markets and products for TRIB. The bottom line is 20%+ CAGR, Operating Earning Goal = 12% (short term goal). Business for FDA approved Uni-Gold HIV product is booming (7 million people tested with this test in 2005). Revenue projected to be $98M 2005 and $115M 2006 with improving operating earnings. A rough calculation would show that EPS should improve from est $0.36 in 2006 to about $0.60 in 2007 if they are successful in getting to the operational earnings level they had prior to 2004. I've owned this stock for a while and have seen two runups to the $26 ($6.50 prior reverse split). The technicals look very good on TRIB as well. To view the TRIB press release go to "presentations" on the TRIB web-site.